The Chicago Athenaeum: Museum of Architecture has announced its 60th annual Good Design Awards, which honor "quality design of the highest form, function, and aesthetic." Guess which paragon of contemporary design won an award this year? An insulin needle. Called the NovoTwist and made by Novo Nordisk for use with insulin pens, this marvel of design has a bayonet fitting that allows "just twist" attachment and detachment to compatible pens, and an audible and tactile "click" that confirms attachment of the needle.
RALEIGH, NC- DiabetesSisters is pleased to announce that registration for the 2011 Weekend for Women Conference in Raleigh, NC will open on January 1, 2011 at 8am. The Conference, a revolutionary national weekend conference designed specifically for women with diabetes, will take place April 29 - May 1, 2011 at the Marriott City Center in downtown Raleigh.
Leaders of the Medicare Diabetes Screening Project (MDSP) announced that twenty community-based organizations from 17 states were given awards of $2,500 each to be used to encourage seniors ages 65 and older who are covered under Medicare to get screened for diabetes.
Calibra Medical has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its FinesseTM insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid-acting insulin. This much-anticipated step closer to market release follows the announcement in January that Calibra received FDA clearance for the device for use with Eli Lilly's Humalog® rapid-acting insulin.
Novo Nordisk announced today the availability of NovoDoseTM - the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo Nordisk's modern insulin analog portfolio: Levemir® (insulin detemir [rDNA origin] injection), NovoLog® (insulin aspart [rDNA origin] injection), and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).
A massive study involving 485 people with type 1 diabetes at 30 locations across North America shows that the combination of an insulin pump and a continuous glucose monitor helps patients achieve significantly lower A1c levels than multiple daily insulin injections.
In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.